Review of advances in the individualized treatment of metastatic colorectal cancer in 2008
- VernacularTitle:2008年转移性结直肠癌个体化治疗进展回顾
- Author:
Yunpeng LIU
- Publication Type:Journal Article
- Keywords:
colorectal cancer;
cetuximab;
K-ras;
oxaliplatin;
irinotecan
- From:China Oncology
2009;19(6):406-408
- CountryChina
- Language:Chinese
-
Abstract:
Oxaliplatin or irinotecan containing chemotherapeutic regimen is the standard treatment for metastatic colorectal cancer (mCRC), which achieves more than 20 months of overall survival. The addition of cetuximab or bevacizumab to the chemotherapy further improves the outcome. The major achievement for the therapy of mCRC in 2008 is the correlation between K-ras status and the efficacy of anti-EGFR therapy. Data from three randomized clinical trials CRYSTAL,OPUS and CELIM have demonstrated that the analysis of K-ras status can help select patients who may benefit from anti-EGFR antibody treatment. The addition of cetuximab to either oxaliplatin or irinotecan containing regimens can benefit mCRC patients with wild-type K-ras tumors, which shows the great superiority of cetuximab in the first-line treatment of mCRC.
